1Perley MJ,Kipnis DM.Plasma insulin responses to oral and intravenous glucose studics:studies in normal and diabetes suhjccts[J].J Clin lnvest,1967,46:1954.
3Tibeduixa EC,Chen C,Beinborn M.A small molccule ligand of the glucagon-like peptide 1 receplor targets its amino-terminal hormone binding domain[J].J Biol Chem,2001,276(41):37787.
4Stoffel M,Expinosa R,Le Bcau MM,et al.Human glucagon-like pcptide 1 reseptor gene:localization to chromosome band 6p21 by fluorescence in situ hybridization and linkge of a highly polymorphic simple tandem repeat DNA polymorphism to ofher markers on chromosome 6[J].Diabetes,1993,42:1215-1218.
5Mentlein R,Gall witz B,schmidt WE.Dipeptide-peptidase IV hydrolyses gastrie inhibitory for their cegradation in human serum[J].Eur J Biochem,1993,214:829.
10Freyse FJ,Becher T,E1 Hag O,et al.Blood glucose lowering and glucagonostaic cffect of glucagon-like peptide l in insulin-deprived diabetic dogs.Diabetes,1997,46:824-828.
二级参考文献5
1Lumelsky N, Blondel O, Laeng P, et al. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science, 2001,292:1389-1394.
2Xie X, Chan RJ, Yoder MC. Thrombopoietin acts synergistically with LIF to maintain an undifferentiated state of embryonic stem cells homozygous for a Shp-2 deletion mutation. FEBS Lett, 2002,529:361-364.
3Drucker DJ. Gut adaptation and the glucagon-like peptides. Gut, 2002,50:428-435.
1Kristin Taylor,.Kate Gurney ,Jenny Han. Exenafide once week- ly treatment maintained improvements in glycemic control and weight loss over 2 years[ J]. BMC Endocrine Disorders ,2011, 11:9.
2Ilaria Dicembrini, Laura Pala, CarloMaria Rotella. From Theo- ry to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors [ J ]. Therapy Experimental Diabetes Re- search,2011:8.
3Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment:insulin resistance and b cell function from fasting plasma glucose and insulin concentrations in man [ J ]. Diabetologia, 1985,28:412- 419.
5Davies R, Donnelly AH, Barnett S, et al. Kilcoyn. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes:re- suits of the Helping Evaluate Exenatide in patients with diabe- tes compared with Long-Acting insulin (HEELA) study [ J ]. Diabetes, Obesity and Metabolism,2009,11 : 1153-1162.
6Craig W, Spellman. Incorporating Glucagon-like Peptide-1 Re- ceptor Agonists Into Clinical Practice [ J ]. JAOA, 2012,112 : s7-s15.
7Ratner D, Maggs LL, Nielsen AH. et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weiglat mefformin-uv.atedpatients with type 2 diabetes mellitus [ J ]. Diabetes, Obesity and Metabolism,2006, 8:419-428.
8陈燕,黄迎燕,方建国等编著.专利信息采集与分析[M]. 清华大学出版社, 2006
9Dr. W. E. Schmidt,E. G. Siegel,W. Creutzfeldt.Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets[J].Diabetologia.1985(9)
